The T2 and T20 kits enable any researcher to instantly access the power of single-cell transcriptomics with no capital commitment at prices as low as $300 per reaction
US-based biotechnology company Fluent BioSciences has launched two breakthrough products for 3′ single-cell RNA analysis.
PIPseq T2 and T20 v3.0 kits capture up to 2,000 and 20,000 single cells or nuclei per reaction, respectively and have been scaled to effectively match various experimental demands.
The company also announced early access to higher scale T200 kits, which will allow the study of up to 200,000 cells in a single sample as well as launched the Epitope Sequencing Kit for multi-omics applications.
Fluent BioSciences co-founder and CEO Sepehr Kiani said: “Fluent BioSciences is breaking down the barriers to entry in the single-cell market with our ground-breaking PIPseq technology and products.
“On the heels of a very successful early access phase, the upgraded v3.0 kits offer improved biological resolution in a benchtop kit to truly enable single-cell analysis in every laboratory across a range of applications from low cell diversity projects to comprehensive solid tissue studies at unprecedented scale, flexibility and cost-efficiency.”
The firm’s Pre-templated Instant Partition (PIPs) platforms enable sensitive single-cell analysis with simple, readily implemented workflows.
PIPseq also offers relatively affordable single-cell analysis because it does not require expensive equipment or complicated microfluidic consumables.
The firm said that any researcher can access the capability of single-cell transcriptome analysis because of PIPseq’s affordable price of $300 for T2 reactions and $900 for T20 reactions.
NYU Langone, New York City Department of Neuroscience Assistant Professor Dr Shane Liddelow said: “The ease with which we have been able to generate large numbers of single-cells for challenging neuronal samples is amazing.
“Sequencing quality, including genes detected, doublet errors, and mitochondrial contamination levels are exceptional, and on par with other methods, and I have no doubt that PIPseq will be an impactful addition to the laboratory repertoire for any researcher.”